Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely associated with these

Insiders' dealing


Report of transactions with shares and related securities of NeuroSearch by
persons discharging managerial responsibilities and person/companies closely
associated with these 

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR.CO) shall make public transactions with shares and related securities
of NeuroSearch A/S by persons discharging managerial responsibilities and
persons/companies closely associated with these. 

Name: Anita Milland 
Reason: Vice President, CFO
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 18 September 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 500
Market value (DKK): 167,500 

Name: Susanna Waters
Reason: Closely related to Nicholas Waters, CEO of NeuroSearch Sweden AB
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 18 September 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 2,500
Market value (DKK): 848,750

Name: Nicholas Waters
Reason: CEO of NeuroSearch Sweden AB
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 19 September 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 2,500
Market value (kr.): 863,750


Asger Aamund
Chairman of the Board


Contact person: 
Anita Milland, Vice President, CFO, telephone: +45 2016 3432
 
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (in preparation for Phase III), tesofensine in
obesity/type 2 diabetes (Phase II), NS2359 in depression (Phase II) and ADHD
(Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II),
ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott,
ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in
bipolar disorder (Phase I) and ABT-107 as well as ABT-560 for the treatment of
various CNS diseases - both (Phase I) in collaboration with Abbott. In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.